Project description:Alzheimer case-control samples originate from the EU funded AddNeuroMed Cohort, which is a large cross-European AD biomarker study relying on human blood as the source of RNA. The design is case-control. Cases are either Alzheimer's disease patients, subjects with mild cognitive impairment or age and gender matched controls.
Project description:Alzheimer case-control samples originate from the EU funded AddNeuroMed Cohort, which is a large cross-European AD biomarker study relying on human blood as the source of RNA. The design is case-control. Cases are either Alzheimer's disease patients, subjects with mild cognitive impairment or age and gender matched controls.
Project description:MicroRNAs (miRNAs) could play an important role as potential Alzheimer Disease (AD) biomarkers. Plasma samples were collected from participants: Mild cognitive impairment (MCI) due to AD patients (n= 20), preclinical AD patients (n= 8) and healthy controls (n= 20). Then, small RNA sequencing analysis, followed by miRNA differential expression analysis comparing different methods (DESeq2, edgeR, NOISeq) were carried out.
Project description:we investigated tear fluid as a novel source of disease-specific protein biomarkers for Alzheimer disease (AD) development using samples from patients suffering from mild cognitive impairment (MCI) and AD. Tear protein content was evaluated via liquid chromatography–mass spectrometry.
Project description:The study recruited 158 participants from the Greek Association of Alzheimer s Disease and Related Disorders (GAADRD) Day Centers between 2016 and 2021. The cohort included 45 individuals with Mild Cognitive Impairment (MCI), 91 with Alzheimer s Disease (AD), and 22 Healthy Controls (HC), diagnosed per DSM V criteria. Comprehensive medical, laboratory, and neuropsychological evaluations were performed to confirm diagnoses.
The analysis was performed using a Waters Xevo G3 QToF Mass Spectrometer coupled with a Waters ACQUITY Premier UPLC. Separation was achieved using a Waters ACQUITY Premier HSS T3 column, with 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) as mobile phases.
Project description:Layer II stellate neurons (entorhinal cortex) and layer III cortical neurons (hippocampus CA1, middle temporal gyrus, posterior cingulate, superior frontal gyrus, primary visual cortex) were gene expression profiled. Brain regions are from individuals who had been diagnosed with mild cognitive impairment. Experiment Overall Design: ~500 neurons were selected from each of 6 brain regions. Total RNA was isolated from each batch of neurons, double round amplified, and hybridized to Affymetrix Human Genome U133 Plus 2.0 arrays.
